Tag: U.K.
-
Trial Shows Rare Disease Drug Treats Covid-19 Patients
Results from a clinical trial show a drug approved for a rare lymph node disease can stabilize or improve the condition of many people with severe Covid-19 complications.
-
Phone App Tracking Covid-19 Symptom Reports
A smartphone app is collecting individual reports about Covid-19 symptoms and other health conditions to provide earlier warnings of outbreaks to health authorities.
-
Start-Up Licenses Immunotherapies in $880M Deal
A new biotechnology enterprise creating treatments that alter chemical functions in immune cells agreed to license its technology to a pharmaceutical company.
-
Business-Foundation Alliance Funds Covid-19 Treatments
Two foundations and a credit card company are providing seed money for development and manufacture of treatments for the novel coronavirus or Covid-19 pandemic.
-
Skin Cancer Apps Shown Misleading, Unreliable
A review of smartphone apps that photograph and purport to analyze skin conditions for signs of cancer shows the apps are unreliable in detecting cancer.
-
Infographic – Mediocre ClinicalTrials.gov Report Rates
New data show most sponsors of clinical trials are not reporting their results on time to a U.S. government web site as required by law.
-
Vaccine Developer Gains $11M in Early Funds
A company designing vaccines delivered with a microneedle patch to prevent infectious diseases is raising $11 million in its first venture funding round.
-
Guidelines Proposed for Complex Clinical Trials
A working group published guidelines for conducting clinical trials that simultaneously test multiple cancer treatments and can change course over time.
-
Commentary – New Models Needed for Antibiotic Resistance
Many parts of a new model for fighting antibiotic resistance are in development, and the pieces still need to be assembled, but the outline of a precision-medicine rather than mass-produced drug model is beginning to emerge.
-
Climate Action Cost Accounting Standard Proposed
A new paper proposes an accounting standard that would require private companies to spell out their costs of meeting net-zero greenhouse gas emissions.